Pharmacologic inhibition of myostatin and related signaling reliably increases lean mass and muscle cross-sectional area, yet trials consistently fail to demonstrate proportional gains in strength or physical function. The dissociation between muscle size and muscle quality undermines the assumption that preserving lean mass is equivalent to preserving capacity. For longevity, the relevant endpoint is force production and functional independence, not tissue volume on a scan.
Key Points
- Myostatin inhibitors enlarge muscle without proportional strength or function gains
- Lean mass is a poor proxy for contractile quality
- Resistance training remains the only intervention improving both size and force
Longevity Analysis
Grip strength, gait speed, and power output predict mortality and disability more reliably than muscle mass measured by imaging, which makes added tissue volume an incomplete surrogate when interpreting trial results or individual body composition data. The interest in these agents stems largely from lean mass loss during GLP-1-mediated weight reduction, but a drug that fills the compartment without restoring contractile quality leaves the underlying deficit intact. Mechanical loading remains the signal that drives mitochondrial density, neural recruitment, and connective tissue remodeling in parallel with hypertrophy — the coordination that pharmacology has so far not reproduced.
Original published by Peter Attia MD, by Peter Attia.